Hypertensive patients with diabetic nephropathy
Conditions
Interventions
High-dose ARB group: Candesartan 12mg/day
low-dose ARB group: Candesartan 4mg/day
Non renin-angiotensin (RA) system inhibiting agents treated group: ARB and angiotensin converting enzyme (ACE) inhibit
Sponsors
University of Tokyo Graduate School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Type 2 diabetes mellitus 2. Diabetic nephropathy: Microalbuminuria (urinary albumin/ creatinin ratio is 30 mg/gCr or above) 3. BP is 130/85 mmHg or above. 4. Serun creatinin is 1.5 mg/dL or below.
Exclusion criteria
Exclusion criteria: 1. Severe hypertension: 180/110 mmHg or above. 2. Severe cardiovascular conplication 3. Severe diabetes 4. Pregnancy 5. History of severe side effect of ARB or ACE inhibitor 6. Patients who are treating with ARB or ACE inhibitor 7. Patients who are inadequate to enty this study by physisicans in charge.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Urinary albumin, urinary protein 2. Serum creatinin | — |
Secondary
| Measure | Time frame |
|---|---|
| Cardiovascular events: cardiovascular death, endstage renal failure, heart failure, stroke, total death Laboratory data: Oxidative stress markers, chest X ray, electrocardiography, carotid artery echo (intima media thickness: IMT), palse wave verosity (PWV), echocardiography (left ventricular mass index) | — |
Countries
Japan
Contacts
Public ContactKatsuyuki Ando
University of Tokyo Graduate School of Medicine Molecular Cardiovascular Metabolism
Outcome results
None listed